***

NASDAQ: CLSD

We see a world without blindness; relentless in our pursuit to preserve and improve vision.

#Confidential and Proprietary |Hello, My name is Daniel White, President and CEO of Clearside Biomedical. Today, I want to present an awesome opportunity for YOUR clients to invest NOW in an IPO.

Clearside is a late stage ophthalmic pharmaceutical company with a proven platform to treat diseases of the eye that lead to blindness .

Our IPO can be ideal for YOUR clients to invest prior to some transformative clinical events in second and third quarter of 2016.

Action: Invest NowEmotion: Save blindness

1

DisclaimerMatters discussed in this presentation may constitute forward-looking statements. The forward looking statements contained in this presentation reflect Clearsides views as of the date of this presentation about future events and are subject to risks, uncertainties, assumptions, and changes in circumstances that may cause Clearsides actual results, performance, or achievements to differ significantly from those expressed or implied in any forward looking statement. Although Clearside believes that the expectations reflected in the forward looking statements are reasonable, Clearside cannot guarantee future events, results, performance, or achievements. Some of the key factors that could cause actual results to differ from Clearsides expectations include its plans to develop and potentially commercialize its product candidates; Clearsides planned clinical trials and preclinical studies for its product candidates; the timing of and Clearsides ability to obtain and maintain regulatory approvals for its product candidates; the extent of clinical trials potentially required for Clearsides product candidates; the clinical utility and market acceptance of Clearsides product candidates; Clearsides commercialization, marketing and manufacturing capabilities and strategy; Clearsides intellectual property position; and Clearsides ability to identify additional product candidates with significant commercial potential that are consistent with its commercial objectives. For further information regarding these risks, uncertainties and other factors you should read the Risk Factors section of Clearsides Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on August 12, 2016, and Clearsides other Periodic and Current Reports filed with the SEC. Clearside expressly disclaims any obligation to update or revise the information herein, including the forward-looking statements, except as required by law. This presentation also contains estimates and other statistical data made by independent parties and by Clearside relating to market size and growth and other data about its industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions and estimates of Clearsides future performance and the future performance of the markets in which Clearside operates are necessarily subject to a high degree of uncertainty and risk.

#Confidential and Proprietary |

2

Targeted Therapy for Retinal and Choroidal Disease

#Confidential and Proprietary |There are 6 reasons YOU want to invest in Clearside Biomedical

We have proprietary accessWe have substantiating clinical data in a pipeling of treatments for multiple blinding diseases that make up multi billion marketsMulti billion dollar marketsOur most advanced program.We have significant clinical events.We are a proven, successful management team

3

The Clearside SCS injection provides access through the suprachoroidal space to the choroid and retina

#Confidential and Proprietary |

4

High drug concentration at disease - Retains drug away from where side effects occurNote: Percentages in the illustrations represent ratio of SCS distribution to intravitreal distribution of triamcinolone to specific tissues in an animal model.

Sclera-choroid & outer retina

12 x

0.2%LensIris-ciliary body3%Target treatmentReduce Side effectsNew Ocular Treatment Paradigm: The SCS injectionClearside Disease Program ObjectivesPosterior SegmentAnterior Segment

#Confidential and Proprietary |But the real story.

Unlike other drug delivery methods, anytime you inject a drug into thie SCS , you change the distribution favorable to disease that affects the retina and choroid.

An unlike other ocular drug delivery methods, SCS injection retains drug away from the areas of the delicate anterior tissues of the eye where side effects may occur.5

INDICATION STUDY DRUGU.S. EST.PREVALENCECURRENT STATUSMacular edema associated with non-infectious uveitis(Uveitis)Zuprata (CLS-TA)Pivotal Phase 3 in progress; data 2H:17RVO (retinal vein occlusion)Zuprata with anti-VEGF(Eylea)Phase 2 data positive; Phase 3 initiation 1H:17Wet AMD(age-related macular degeneration)AxitinibPre IND meeting Q4:16Retinal Vascular DiseaseProprietary compoundPreclinicalOrphan diseasesGene therapyPreclinical

~350K~2.2M~1.2M